Open original FDA record ↗Recall record
- FDA identifier
- Z-2339-2017
- Company in FDA record
- bioMerieux, Inc.
- FDA classification date
- Jun 29, 2017
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
Complaints were received from customers observing falsely overestimate results or external quality control higher results than expected when performing tests with VIDAS Testosterone.
Source facts
- Action
- An Urgent Product Safety Notice was sent on 5/15/2017 to consignees. The Notice requested that they discontinue use and discard any remaining inventory of the product, and to identify any possible falsely over estimated results and determine appropriate actions if relevant. The Notice also included a response form to be returned to Biomerieux.
- Initiated
- 2017-05-15
- Root cause
- Under Investigation by firm
- Terminated
- 2020-06-11
- Distribution
- AR, CA, CO, GA, IL, IA, MI, MN, MT, NY, OK, TN, TX, WY, Columbia, Costa Rica, El Salvador, France, Hong Kong, Jordan, Nicaragua, Russian Fed., Sri Lanka, Sweden, Ukraine
- Recall number
- Z-2339-2017
- Recall status
- Terminated
- CDRH record ID
- 155630
- FDA classified
- 2017-06-29
- Recall event number
- 77292